Preventing low platelets from chemo in cervical cancer
Treatments studied
Part of Blood & lymphatic, Cancer, Injuries & trauma, Women’s health & pregnancy clinical trials.
This trial studies a pill called herombopag to see if it can prevent low blood platelets caused by chemotherapy (and sometimes radiation) in people with cervical cancer. Low platelets increase the risk of bleeding, and this drug may help keep platelet levels safer so you can continue your cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has spread within the pelvis but not to distant organs (stage IB3 to IVA).
- You are 18 years or older and generally able to care for yourself (ECOG score 0-1).
- You are about to receive or are receiving a standard chemotherapy that includes cisplatin every 3 weeks.
- After your last chemo cycle, your platelet count was low (below 75,000) and you have at least one risk factor for bleeding, such as prior bleeding, certain chemo drugs, or radiation to the pelvis.
- Your doctor expects you to live at least 12 weeks and be able to continue chemo for at least one more cycle.
- You do not have other blood disorders, recent blood clots, severe heart problems, or major organ (liver/kidney) issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial tests a medication called Herombopag to raise platelet counts in adults aged 60 or older with immune thrombocytopenia (ITP). The goal is to see if it is safe and effective for this age group.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This study tests an oral medication, hetrombopag, to see if it can safely raise platelet counts in people with gynecologic cancers whose platelets drop too low from chemotherapy or other cancer treatments. It may help them continue their cancer therapy without delays or bleeding risks.
Hear when a new Thrombopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.